ACM Biolabs was founded in Singapore in 2013 to develop its proprietary polymer-based delivery platform. ACM Biolabs with operations in Singapore, Basel, Switzerland and Sydney, Australia is developing next generation immune-modulators, infectious disease vaccines and cancer therapeutic vaccines. Our lead asset, ACM-001, uses polymersomes to deliver SARS-CoV-2 beta variant antigen is being tested both intranasally and intramuscularly in Phase 1 studies. ACM Biolabs with its proprietary and non-immunogenic, inert delivery platform to deliver proteins, peptides, mRNA and oligonucleotides to revolutionize vaccines and therapies.
We continue to build a world-class team of specialists and are looking for:
SGP-L-1005-22-11-S | 10 November 2022
ACM Biolabs Pte LTD is an innovative biotechnology company situated on the NTU campus closely working with ACM Biosciences AG in Basel, Switzerland. We use a revolutionary new technology to advance the boundaries of human health in the field of vaccinations and therapeutics.
At ACM Biolabs we are focused on developing novel vaccines using our proprietary artificial cell membrane (“ACM”) technology. With ACM Technology, we are able to incorporate multiple antigens (Proteins/Peptides/mRNA) in polymeric nano-vesicles, allowing them to induce a strong immune reaction. We have demonstrated efficacy via both injected and oral dosages using multiple antigens and have a growing pipeline of vaccines. Our current focus is to progress ACM-COVID vaccine further in clinical development, along with a rich pipeline of infectious disease and immunoncology vaccines.
About the job:
You will be responsible for various product development projects focusing on therapeutic cancer vaccine and prophylactic infectious disease. Your scientific tasks include:
ACM Biolabs offers a competitive salary package. Please note, only shortlisted candidates will be notified. Please send your CVs to firstname.lastname@example.org